Pursuing higher quality pharmaceuticals by combining group strengths
In 2002, Taiho Pharmaceutical established the U.S. subsidiary Taiho Oncology, Inc., to provide direct management of research and development programs for obtaining marketing approval of anticancer drugs primarily in the U.S. and European markets. The selected professional team works together with medical professionals and organizations in the U.S. and Europe, while cooperating with Taiho Pharmaceutical staff in Japan, to advance the global development of new drugs that can contribute to cancer treatment. As a direct result of these efforts, the New Drug Application for a new anticancer drug TAS-102 (brand name "LONSURF") was approved in September 2015 by the U.S. FDA and the product was commercially launched by Taiho Oncology in October 2015. The Marketing Application is currently under review by the EMA in the European Union.
|Company Name||TAIHO ONCOLOGY, INC.|
|Established||August 8, 2002|
|Representative||Eric Benn, President & CEO|
|Business||Clinical development and commercialization of anticancer drugs|
|Head office||101 Carnegie Center, Princeton,
New Jersey 08540 USA
* Please click the link below to see Taiho's latest product pipeline information.
Taiho Pharma Europe, Ltd. (TPEL), located in Uxbridge, UK, was established in February 2009 as a subsidiary of Taiho Pharmaceutical Co., Ltd. Working closely with the professional R&D teams in Japan and the US, TPEL provides direct management of research and development programs and regulatory affairs support toward obtaining marketing approval of anticancer drugs in the European markets.
|Company Name||TAIHO PHARMA EUROPE, LTD.|
|Established||February 11, 2009|
|Representative||Eric Benn, Director|
|Business||Clinical development of anticancer drugs|
|Head office||1 Furzeground Way, Stockley Park, Uxbridge, UB11 1BD UK
Tel: +44 (0)208 622 3294
In August 2008, Taiho Pharmaceutical established the Chinese subsidiary, Taiho Pharmaceutical of Beijing Co., Ltd. Taiho Beijing conducts clinical development to obtain approval from authorities in China on anticancer agents researched and developed by Taiho Pharmaceutical, and it provides information to Chinese oncologists. In July 2009, the company put TS-1 on the market and is currently developing its business mainly in China's coastal areas. Aiming to gain broad recognition of Taiho among the Chinese people as a specialty pharma leader in anticancer agents, the company is contributing to cancer treatment in China by providing oncologists, other medical care professionals, and patients with effective drugs to support them in the battle against cancer.
|Company Name||Taiho Pharmaceutical of Beijing Co., Ltd.|
|Established||August 8, 2008|
|Representative||Shingo Seki, General Manager|
|Business||Providing information on pharmaceuticals and clinical development work|
|Head office||9F-9A3, Hanwei Plaza, 7th,
Guanghua Rd., Chaoyang Dist.,
Beijing City 100004 China
Taiho Pharma Singapore Pte. Ltd. was established in Singapore in August 2011 as a subsidiary of Taiho Pharmaceutical Co., Ltd. Sticking with its philosophy “by local, for local,” Taiho Pharma Singapore covers a wide range of jobs such as regulatory affairs, medical affairs and sales of anticancer drugs as a hub for Taiho's oncology business in South East Asia in close touch with local medical oncologists and the other medical professionals in cancer care. Taiho Pharma Singapore hopes to share smiles and happiness with local cancer patients, medical oncologists and the other medical professionals in cancer care in South East Asia by introducing anticancer drugs and data with high quality.
|Company Name||Taiho Pharma Singapore Pte. Ltd.|
|Established||August 8, 2011|
|Representative||Yoshimasa Nishimura, Managing Director|
|Business||Import/export, sales and marketing of pharmaceuticals|
|Head office||390 Havelock Road #06-07, King's
Centre 169662 Singapore
TAIHO VENTURES, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co. Ltd., established in the U.S. in 2016. Taiho Ventures is a strategic investor looking at early stage preclinical oncology companies as well as platform technology companies for Taiho’s core therapeutic areas. TAIHO VENTURES will review the wide variety of modalities for both biologics and small molecules mainly in the U.S. and European countries. The company will also consider the option-type of investments and spin-outs, in addition to the pure equity investments.
|Company Name||TAIHO VENTURES, LLC|
|Established||April 15, 2016|
|Representative||Sakae Asanuma, President|
2420 Sand Hill Rd, Suite 203, Menlo Park, CA 94025, USA